Caribou Biosciences, Inc. · NASDAQ:CRBU
Caribou Biosciences — 2026 Tandem Meetings
19 slides from Caribou Biosciences's conference presentation, Feb 7, 2026
Slide 1: CB-011, an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking, in r/r MM
CB-011, an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking, in patients with relapsed/refractory Multiple Myeloma (r/r MM) Dose escalation results from the CaMMouflage phase 1 trial Presented by: Adriana Rossi, MD Mount Sinai 2026 TANDEM MEETING - SALT LAKE CITY, UT - FEBRUARY 7, 2026 A
Slide 2: Disclosures
Disclosures Adriana Rossi • Consultant • JNJ, BMS, Caribou Biosciences, Kite, Karyopharm
Slide 3: Allogeneic CAR-T cell therapy can fill unmet need in MM
Allogeneic CAR-T cell therapy can fill unmet need in MM Bispecifics CB-011 Treatment Repeat dosing Single-dose treatment burden until relapse Weekly or bi-weekly High response rates2 Efficacy treatment required for with single dose durability High rates with Lower rates of infection2 Infection limit
Slide 4: Allogeneic CAR-T cell therapy can fill unmet need in MM
Allogeneic CAR-T cell therapy can fill unmet need in MM Bispecifics CB-011 Auto CAR-T Treatment Repeat dosing Single-dose treatment burden Overcomes access Access 1 of 10 MM patients until relapse challenges to receive auto CAR-Ts3 treat more patients No wait needed Weekly or bi-weekly High response
Slide 5: CB-011 key attributes
CB-011 key attributes First allogeneic anti-BCMA CAR-T cell therapy with immune cloaking Manufactured using Cas12a chRDNA genome-editing technology Immune cloaking implemented through: • B2M gene KO to slow down T cell-mediated B2M–HLA-E rejection • B2M–HLA-E-peptide fusion insertion to blunt NK cel
Slide 6: CB-011 CaMMouflage Phase 1 trial (NCT05722418)
CB-011 CaMMouflage Phase 1 trial (NCT05722418) Eligibility Lymphodepletion regimens evaluated • ≥3 prior lines of therapy, including a PI, an IMiD, and an • 300 mg/m2 cy and 30 mg/m2 flu daily x 3 days anti-CD38 antibody • 500 mg/m2 cy and 30 mg/m2 flu daily x 3 days Exclusion CB-011 dose levels eva
Slide 7: 48 patients treated in dose escalation of CaMMouflage trial
48 patients treated in dose escalation of CaMMouflage trial Initial LD regimen (N=13) LD: 300 mg/m2 cy and 30 mg/m2 flu daily x 3 days CB-011 dose levels evaluated: 50M, 150M, 450M CAR-T cells Outcomes: • No DLTs observed • Minimal cell expansion and efficacy observed • 1 patient had robust cell exp
Slide 8: CaMMouflage trial: baseline and disease characteristics
CaMMouflage trial: baseline and disease characteristics Patients treated with Patients treated with All patients1 Patient and disease characteristics initial LD regimen2 selected LD regimen3 (N=48) (N=13) (N=35) Age, years, median (range) 68.5 (49-84) 68.0 (49-84) 69 (53-82) Male, n (%) 33 (68.8) 9
Slide 9: CaMMouflage trial: efficacy
CaMMouflage trial: efficacy Responses observed at all CB-011 doses with selected LD Selected LD All patients 500 mg/m2 cy and 30 mg/m2 flu daily x 3 days N=48 all dose levels1 N=35 All cell doses at 150M 300M 450M 800M selected LD N=6 N=13 N=13 N=3 N=35 BCMA naïve BCMA naïve BCMA naïve BCMA naïve BC
Slide 10: Initial LD regimen: longest responder remains in stringent CR with sustained MRD negativity
Initial LD regimen1: longest responder remains in stringent CR with sustained MRD negativity beyond 21 months Day 28 3 mo 6 mo 9 mo 12 mo 15 mo 18 mo 21 mo 24 mo MRD CB-011 EMD neg 2 dose (Y/N) (Y/N) 300 mg/m2 cy and 30 mg/m2 flu x 3 50M Y N 50M N NE 50M Y NE 150M N N 150M Y NE days 150M N Y 150M N
Slide 11: CB-011 induces deep and durable responses at recommended dose for expansion in BCMA-naïve patients
CB-011 induces deep and durable responses at recommended dose for expansion in BCMA-naïve patients1 92% ORR 75% ≥CR rate 91% MRD neg 7 of 12 ≥VGPR at (11/12) (9/12) (10/11 evaluable patients) ≥6 months MRD EMD neg2 Day 28 3 mo 6 mo 9 mo 12 mo 15 mo 500 mg/m2 cy and 30 mg/m2 flu x 3 days (Y/N) (Y/N)
Slide 12: CaMMouflage trial: safety and tolerability
CaMMouflage trial: safety and tolerability No GvHD, IEC-EC, parkinsonism, or cranial nerve palsies observed at any dose level BCMA-naïve 450M at All at selected LD1 • Notable AEs are manageable selected LD1 (N=35) (N=12) • 3 events of note at 450M dose level: • 1 grade 5 ICAHT (CB-011-related) on da
Slide 13: CB-011 expansion is associated with LD regimen and clinical outcome
CB-011 expansion is associated with LD regimen and clinical outcome Absolute number of CAR+ cells/µL 500 Cy Absolute number of CAR+ cells/µL 500 Cy (N=34) Responders (N=23) 300 Cy (N=13) Non-responders (N=11) Days Days Measurement 500 Cy 300 Cy Non- Measurement Responders responders Tmax (median) Da
Slide 14: Highest cell expansion at 450M dose level with selected LD
Highest cell expansion at 450M dose level with selected LD CB-011 PK by dose with selected LD Flow PK data up to Day 28 visit from 34 of 35 patients treated with 500 mg/m 2 cy and 30 mg/m2 flu daily x 3 days; arithmetic mean with SE shown by dose level Data cutoff 24Sept2025
Slide 15: CB-011 exhibits central memory CD8 T cell phenotype at peak of expansion
CB-011 exhibits central memory CD8 T cell phenotype at peak of expansion CD8 CAR+ T cell memory phenotypes at peak of expansion (Cmax) 59.6% 4.9% CM SCM/naive CM EM CCR7 SCM 3.3% naive TE 32.2% TE EM CD45RA Data sho wn for 450M d ose with selected LD patients with at least 100 CAR+ CD8 T cell events
Slide 16: Depth of lymphodepletion associated with improved patient outcomes
Depth of lymphodepletion associated with improved patient outcomes Endogenous T cells at Day 0 Endogenous T cells at Day 0 for by LD dose of cytoxan selected LD by response
Slide 17: Rapid recovery of endogenous T and NK cells may contribute to the manageable safety profile
Rapid recovery of endogenous T and NK cells may contribute to the manageable safety profile • Patient T cell depletion enables CAR-T T cells cell expansion log10(ABS+1) NK cells • Fast recovery of T and NK cells quickly reinstates the patient’s natural immunity, likely contributing to the favorable
Slide 18: CaMMouflage trial conclusions and next steps
CaMMouflage trial conclusions and next steps • Deep, durable responses observed with CB-011 in heavily pre-treated r/r MM patients • Longest responder remains in sCR with sustained MRD negativity beyond 21 months • 92% ORR, 75% ≥ CR rate, 91% MRD negativity, and 7 of 12 ≥VGPR at ≥6 months at the rec
Slide 19: Gratitude for patients, caregivers, investigators, and site staff
Gratitude for patients, caregivers, investigators, and site staff Mt. Sinai MCW MSKCC Cleveland Hackensack Clinic Huntsman OHC VCU U of Colorado Kentucky Duke Tennessee Levine Oncology UAB CaMMouflage trial sites UTSW Miami